

NCSP Guidelines for managing women with abnormal cervical cytology

Margaret Sage 2019

NCSP Guidelines Sept 2008

hrHPV Testing was introduced on October 2009 for women in selected clinical groups

Guidelines for Cervical Screening in New Zealand

Incorporating the Management of Women with Abnormal Cervical Smears



hrHPV Testing in New Zealand

- 1. Triage of Women 30 years and over with ASC-US or LSIL (who have not had an abnormal cytology sample within the last 5 years)
- 2. Follow-up of women treated for high-grade squamous lesions (Test of cure)
- 3. Post-colposcopy management of women with discordant results: e.g. high-grade cytology and negative satisfactory colposcopy (specialist testing)

Women with unsatisfactory cervical smears

Report: Unsatisfactory

Rec: Repeat cervical cytology within 3 months

Refer for colposcopy after three consecutive unsatisfactory smear reports

Women with **normal** or no previous cervical smears

Report: Negative for intra-epithelial lesion or malignancy (squamous or glandular)

Rec: Repeat cytology in three years unless....

......this is the first smear, or more than 5 years has elapsed since the previous smear: then

Rec: Repeat cytology in 12 months

Women with low-grade squamous abnormalities

Report: Atypical squamous cells of undetermined significance (ASC-US) or Low grade squamous intraepithelial lesions (LSIL – CIN1)

Rec: 1. Women 20-29 yrs

- with no previous abnormal in last 5 years: Repeat cervical cytology
 in 12 months.....next slide
- with a previous abnormal in last 5 years: Referral for colposcopy

2. Women 30+yrs

- with no previous abnormal in the last 5 years: Reflex HrHPV test
 next slide
- with a previous abnormal in 5 last years: Referral for colposcopy

Women with low-grade squamous abnormalities (cont.)

Women 20-29 years

with 12 month repeat smear after first ASC-US/LSIL

Report: negative further repeat sample in 12 months

Report: any abnormality referral to colposcopy

Women 30+ years

HrHPV Test: negative repeat cytology in 12 months

HrHPV Test: positive referral to colposcopy

Women with **high-grade** squamous abnormalities

Report: Atypical squamous cells, possible high-grade (ASC-H)

Rec: Refer to colposcopy

Report: HSIL

Rec: Refer for colposcopy

Report: SCC or HSIL with features suspicious of invasion

Rec: Urgent referral to experienced colposcopist or

gynaecologic oncologist

- 35 years of age
- normal NCSP history, regular three yearly samples
- asymptomatic, normal clinical examination
- Cytology: ASC-US
- What should happen next??

- 35 years of age
- normal NCSP history, regular three yearly samples
- asymptomatic, normal clinical examination
- Cytology: ASC-US
- High-risk HPV test: Detected
- Recommendation: Refer for colposcopy
- Colposcopic findings: Low-grade changes observed
- Punch biopsy taken: CIN1 confirmed
- Referred to sample-taker for 2 annual follow-up cytology samples
- Both negative so returned to three yearly screening.

- 31 years of age
- cytology 3 years previously was normal, but one sample 7 years previously showed ASC-US
- asymptomatic, normal clinical examination
- Cytology: ASC-US
- High-risk HPV test: Not Detected
- Recommendation: Repeat cytology in 12 months
- Repeat cytology: LSIL
- Refer to colposcopy

- 22 years of age
- Asymptomatic, cervix appears normal
- First cervical cytology sample
- Cytology: LSIL
- Repeat cytology: ASC-US
- Referral to colposcopy

- 42 years of age
- CIN 2 treated 10 years previously. Normal annual cytology samples since.
- Asymptomatic, cervix appears normal
- Cytology: HSIL
- Referral to colposcopy
- At colposcopy: HSIL seen and confirmed on biopsy
- Treated with a LLETZ: CIN 3, completely excised
- Post-treatment colposcopy at about 8 months, then repeat cytology plus hrHPV test (first pair of Test of cure) at 12 months

- 23 years of age
- First cytology sample
- Asymptomatic, cervix appears normal
- Cytology: Atypical Squamous Cells, possible high-grade (ASC-H)
- Recommendation: Referral to colposcopy
- Colposcopy satisfactory (SCJ fully visualised)
- Minor changes only seen: Cervical biopsy inflammation only
- hrHPV test: Detected (Specialist ordered)
- MDM discussion: recommends LLETZ: HSIL on histology

- 63 years of age
- LSIL 15 years previously: normal samples since.
- Two recent episodes of vaginal bleeding, cervix looks normal
- Cytology: Normal (atrophy)
- Recommendation: Referral to colposcopy
- Colposcopy difficult because of marked atrophy. SCJ not fully visualized. Colposcopic impression: HSIL
- Biopses: CIN 3. Repeat cytology: HSIL, possible invasion
- Cone performed because upper limit of SCJ not seen: HSIL with focus of SCC in the endocervical canal

Women with histologically confirmed LSIL

- Treatment not recommended as such lesions are considered to be an expression of a productive HPV infection
- Refer back to smear-taker for repeat cytology at 12 and 24 months.

If both repeat samples negative return to routine screening

If either repeat sample shows any abnormality then refer back to colposcopy

Women with histologically confirmed HSIL

Women with histologically confirmed CIN 2 or 3 should be treated Exceptions: 1. CIN2/3 in pregnancy

2. Women under 25 years of age with CIN2

LLETZ: excisional treatment

Most lesions are treated this way in New Zealand

Cone Biopsy: may be used if there is

- 1. Extensive HSIL
- 2. Failure to visualize the upper limit of the transformation zone with high-grade cytology
- 3. Suspicion of early invasive cancer on cyto/colp/histo
- 4. Suspected presence of a glandular lesion on cyto/histo

Follow-up after treatment Women treated for CIN 2 or 3

- colposcopy +/- cytology at about 8 months (6-12 months) post-treatment
- cytology and HPV Test @12 months after treatment (Test of Cure – first round)
- If both negative, repeat cyto and HPV Test@ 12 months (Test of Cure second round)
 - If both negative again, return to 3 yearly screening
 - If any tests are abnormal/positive, return to colposcopy
- any abnormal smear within 5 years after treatment: referred to colposcopy

Women with glandular abnormalities

Report: Atypical glandular cells (AGC) or endocervical adenocarcinoma in situ (AIS)

Rec: Refer to an experienced colposcopist or gynaecological oncologist

Report: Adenocarcinoma

Rec: Urgent referral to gynaecological colposcopist or a

gynaecologic oncologist

Special clinical circumstances Pregnancy

Cervical cytology taken as per NCSP guidelines

Low-grade cytology: as per guidelines

High-grade cytology: refer for colposcopy

Colposcopy: aim is to exclude invasive cancer

- biopsy if invasion suspected otherwise treatment deferred until after delivery
- May need further colposcopies during pregnancy

Special clinical circumstances Immunosuppressed women

Refer all abnormalities for colposcopy

Assessment and treatment should be by an experienced colposcopist

The whole of the lower genital tract needs evaluating

Treatment should be by excisional methods

Follow-up after treatment should include colposcopy as well as cytology

Follow-up should be annual and indefinite

Special clinical circumstances Post-menopausal women and women over 40 years with normal endometrial cells

Normal endometrial cells

Normal endometrial cells in pre-menopausal women are rarely associated with endometrial pathology such as endometrial carcinoma and if asymptomatic, no further investigation is recommended.

Normal endometrial cells in post-menopausal women is more often associated with significant endometrial pathology and further investigation should be considered: management is determined by the clinician, considering clinical symptoms, LMP, HRT, use of contraceptives etc

Women with symptoms of uterine pathology require investigation regardless of cervical smear results

Atypical endometrial cells Urgent referral to an experienced colposcopist

Special clinical circumstances Women who have had a hysterectomy

Subtotal hysterectomy: routine screening

Total hysterectomy for benign reasons:

if benign and normal smears in previous 5 years, no further smears

if smear history is unknown then baseline vault smear

if normal, no further smears

if CIN 1 on histology at any time in past then

3 yearly vault smears until 70 years

Total hysterectomy for CIN 2 or 3:

if HSIL on histology at any time then annual vault smears until 70 yrs HPV testing for test of cure can occur at 12 months after treatment

Total hysterectomy for genital malignancy:

on-going surveillance from a gynaecological oncologist

Clinical Practice Guidelines for Cervical Screening in New Zealand

<u>https://www.nsu.govt.nz/health-professionals/national-cervical-screening-programme</u>

Will be revised when HPV testing is introduced as the primary screening test in 2021